On World Kidney Day (WKD) 2016 (March 10), The Lancet and the International Society of Nephrology (ISN) launched an online campaign to raise awareness of acute and chronic kidney diseases and bring together the best available evidence to inform strategies to reduce national, regional and global burden of the disease and its risk factors.
The Lancet Kidney Campaign builds on ‘0by25’, the International Society of Nephrology 2015 Lancet Commission, which called for the elimination of preventable deaths from acute kidney injury by 2025.
The Campaign brings together research and analysis on acute kidney injury (AKI), chronic kidney disease (CKD), and dialysis and transplantation from across The Lancet journals. Also launched was a video in partnership with ISN, including interviews with ISN President Adeera Levin, Past President Giuseppe Remuzzi, and President Elect David Harris.
The Campaign will provide monthly updates on advances in nephrology as well as expert commentaries and interviews on key health and policy issues relevant to kidney disease.
“Despite its devastating effects, kidney disease is not usually part of national health strategies, and does not receive the funding or research attention afforded to other chronic diseases” wrote the ISN leadership and The Lancet Editor-inChief Dr Richard Horton. “It is imperative that evidence is presented to push kidney disease to the forefront of national and global health agendas.”
Kidney disease is increasingly recognised as a major public health problem worldwide. About one in ten adults have evidence of CKD, the prevalence of advanced CKD is rising worldwide, and the fastest growth is occurring in low- and middle-income countries. The incidence of AKI has also increased substantially over last 20 years and is an important driver of CKD and kidney failure.
Although renal replacement therapies (RRT) are more available in high income countries, namely dialysis and transplantation, access to it is limited in many countries, and as few as 25% of patients requiring RRT globally do not get it. For more information, please visit The Lancet website.